SOShusaku Omoto

Shusaku Omoto

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Shusaku Omoto has a total of 63 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Cardiac Sympathetic Dysfunction Reveals Asymmetric Dopaminergic Neurodegeneration in Drug-naive Parkinson Disease

    by Tadashi Umehara, Yoshitaka Nakayama, Hiromasa Matsuno, Shusaku Omoto, Renpei Sengoku, Hidetomo Murakami, Yasuyuki Iguchi

    Purpose: Asymmetric nigrostriatal dopaminergic degeneration in Parkinson disease (PD) is linked to motor and nonmotor manifestations and may reflect Lewy body propagation patterns, particularly in brain-first pathology. The clinical determinants of nigrostriatal dopaminergic asymmetry, however, remain unclear. Methods: We studied 121 drug-naive patients with PD to examine associations between the striatal asymmetry index (AI) and clinical features, including olfactory function, constipation, and cardiac sympathetic dysfunction measured by 123 I-metaiodobenzylguanidine (MIBG) scintigraphy. Results: Patients with pronounced striatal asymmetry (AI >20%) exhibited lower prevalences of hypertension and smoking, a higher frequency of tremor-dominant phenotype, and predominantly right-sided motor symptoms compared with those with symmetric dopaminergic degeneration (AI ≤20%). They also had higher cardiac 123 I-MIBG uptake and less severe orthostatic blood pressure decline. Unexpectedly, olfactory dysfunction severity was not associated with striatal AI. Multivariable regression analysis revealed that cardiac sympathetic dysfunction independently and robustly correlates with symmetric degeneration of nigrostriatal dopaminergic neurons (β=0.287, t =3.032, P =0.003). Hierarchical clustering grouped cardiac sympathetic dysfunction and striatal AI in the same lowest-level cluster (linkage dissimilarity = 0.66), indicating a close association. Patients exhibiting markedly reduced cardiac 123 I-MIBG uptake demonstrated more symmetric dopaminergic degeneration compared with those with normal uptake (striatal AI: 10.8±10.2% vs. 23.5±15.8%; P =0.003). Conclusions: Cardiac sympathetic Lewy body burden appears to play a central role in shaping nigrostriatal dopaminergic asymmetry in early PD. Cardiac sympathetic denervation may act as a phenotypic modifier, influencing the spatial pattern of neurodegeneration and contributing to clinical heterogeneity.

  • Open Access

    The utility of a cognitive function assessment tool for detecting psychological and physical factors contributing to impaired cognitive abilities in workers

    by Shusaku Omoto, Setsuo Kinoshita, Keiji Masuda

    労働者の高ストレス,睡眠不足等の心理,身体的負荷は集中力の低下等の認知機能低下を引き起こし,労働災害や労働生産性の低下の誘因となる.時間見当識課題に対する回答および音声特徴量を用いて,認知症における認知機能低下を検知可能なスマートフォンアプリケーションであるONSEIⓇを用いて労働者の心理,身体的要因による認知機能低下の検出が可能か予備的検討を実施した.153名(年齢中央値47歳)の労働者を対象に60日間毎日リマインドのメールを送付し,ONSEIⓇの実施,及び当日の心理,身体症状と前日の睡眠状況や飲酒量についてのアンケートへの回答を依頼した.その結果,毎日のアンケートで,当日の気分の落ち込みや不安がある被験者では有意にONSEIⓇが陽性となることが多かった(オッズ比 1.87,p<0.01).一方,自覚的な体調不良,前日の睡眠障害,多量の飲酒は,ONSEIⓇ陽性と有意な関連はなかった.試験終了後の行動変容に関するアンケートでは,認知,精神の健康に関する認識の変化,および適切な睡眠と水分補給の心がけの変化がみられた.本研究の結果から,気分の落ち込みや不安でONSEIⓇの陽性率が上昇することが示唆されたが,その検知感度はスクリーニングツールとしては十分ではなかった.一方,このような取り組みにより労働者の心理的,身体的健康に対する認識の変化や行動変容が得られる可能性が示唆された.


  • Effects and safety of high-frequency rTMS in acute intracerebral hemorrhage patients: A pilot study

    by Teppei Komatsu, Takuya Hada, Nobuyuki Sasaki, Hiroyuki Kida, Junichiro Takahashi, Takahiro Maku, Ryoji Nakada, Tomotaka Shiraishi, Shiho Akiyama, Tomomichi Kitagawa, et al.


  • Asymmetric focal cortical atrophy in CSF1R-related leukoencephalopathy; case report

    by Teppei Komatsu, Maki Takahashi, Shusaku Omoto, Yasuyuki Iguchi

  • The association between urinary pentosidine levels and cognition in drug-naïve patients with Parkinson’s disease

    by Shusaku Omoto, Mitsuru Saito, Hidetomo Murakami, Tomotaka Shiraishi, Tomomichi Kitagawa, Takeo Sato, Hiroki Takatsu, Teppei Komatsu, Kenichiro Sakai, Tadashi Umehara, et al.

    Advanced glycation end products (AGEs) are suggested to play a potential role in the progression of Parkinson’s disease (PD). The association between urinary levels of pentosidine, one of the best-characterized AGEs, and clinical conditions such as motor severity and cognition were investigated in patients with PD. Data on the clinical characteristics and urinary levels of pentosidine for 44 drug-naïve patients aged 60 years or older with PD were collected. The association between urinary pentosidine levels and severity of motor symptoms and cognition was analyzed using the Montreal Cognitive Assessment Scale (MoCA). Urinary pentosidine values increased with age (R2 = 0.286, p < 0.001) and were negatively correlated with the MoCA score (R2 = 0.255, p = 0.001). Urinary pentosidine levels were significantly correlated with age (r = 0.535, p < 0.001), Hoehn-Yahr stage (r = 0.340, p < 0.05), and total MoCA score (r = − 0.505, p < 0.001). Multiple linear regression analysis showed that older age (β = 0.543; 95% confidence interval [CI] 0.300, 1.307; p = 0.003) was significantly associated with severity of motor symptoms, and that older age (β = − 0.456; 95% CI − 0.287, − 0.054; p = 0.005) and urinary pentosidine levels (β = − 0.311; 95% CI − 0.428, − 0.004; p = 0.046) were significantly associated with a lower MoCA score. Urinary pentosidine levels were significantly associated with lower cognition in drug-naïve PD patients. These findings have important clinical implications and suggest that pentosidine may be a potential marker for cognitive impairment in early PD.


  • Cauda Equina Atrophy in Amyotrophic Lateral Sclerosis on Routine Lumbar Magnetic Resonance Imaging

    by Satoshi Matsushima, Shusaku Omoto, Tetsuya Shimizu, Akira Baba, Hiroya Ojiri

    Objective: The aim of the study was to evaluate the cross-sectional area of the cauda equina in amyotrophic lateral sclerosis (ALS) on routine lumbar magnetic resonance imaging and investigate the diagnostic accuracy in comparison with age- and sex-matched non-ALS controls. Methods: This retrospective study included 15 ALS patients and 15 age- and sex-matched non-ALS controls. Two independent neuroradiologists measured and compared the total cross-sectional area of the cauda equina of ALS patients and the non-ALS controls at the level of the L3 and L4 using axial T2-weighted images. The cutoff value, sensitivity, specificity, and area under the curve were measured. The interobserver reproducibility of the 2 independently obtained measurements was evaluated. Results: The total cross-sectional area of the cauda equina in the ALS group was significantly smaller than that in the non-ALS group (L3: median, 66.73 vs 90.19 mm2, P < 0.001; L4: median, 52.9 vs 67.63 mm2, P < 0.001). The cutoff values at L3 and L4 were 76.95 and 61.04 mm2 with a sensitivity and specificity of 1 and 0.87 and 0.8 and 0.87, respectively. The area under the curve at L3 and L4 were high at 0.96 and 0.94, respectively. The interobserver reproducibility was 0.88 at L3 and 0.89 at L4. Conclusions: The ALS patients showed significant atrophy of the cauda equina compared with non-ALS patients.


  • Crossed Choreoathetosis Caused by Unilateral Thalamic Hemorrhage

    by Sumire Kurihara, Takeo Sato, Hidetomo Murakami, Teppei Komatsu, Kenichiro Sakai, Tadashi Umehara, Shusaku Omoto, Hidetaka Mitsumura, Yasuyuki Iguchi

  • Risk factors for minor hallucinations in Parkinson's disease

    by Shusaku Omoto, Hidetomo Murakami, Tomotaka Shiraishi, Keiko Bono, Tadashi Umehara, Yasuyuki Iguchi

    Objectives Minor hallucinations (MHs), including sense of presence, passage hallucinations, and visual illusions, have been reported in Parkinson’s disease (PD). Here we investigated the prevalence and associated risk factors for MHs according to appearance time. Methods Data on the clinical characteristics and the appearance time of MHs for 100 PD patients were collected using a questionnaire and analyzed. MHs were classified into two groups according to the time when MHs appeared: MHs appearing while awake during the daytime (dMHs) and MHs appearing at arousal from sleep during the night or early morning (aMHs). Results Thirty‐eight patients (38%) experienced MHs. dMHs and aMHs were present in 21 (21%) and 28 patients (28%), respectively. Compared to patients without MHs, patients with dMHs had more severe motor symptoms, longer disease duration, higher levodopa equivalent daily dose (LEDD), higher rate of cognitive impairment, and visual hallucinations during the daytime, whereas patients with aMHs had a higher rate of rapid eye movement sleep behavior disorder (RBD), longer disease duration, higher LEDD, and higher dopamine agonist dosage. Logistic regression analysis showed that cognitive impairment was significantly associated with dMHs (odds ratio (OR) 7.292, p = 0.001), and that RBD (OR 8.306, p < 0.001) and LEDD (OR 1.002, p = 0.049) were significantly associated with aMHs. Conclusions Patients with MHs have different clinical characteristics according to the time when MHs appear. These findings have important clinical and prognostic implications and suggest appropriate therapeutic options for psychotic symptoms.


  • Neuronal intranuclear hyaline inclusion disease presenting with childhood-onset night blindness associated with progressive retinal dystrophy

    by Shusaku Omoto, Takaaki Hayashi, Hiromasa Matsuno, Hitomi Higa, Shuhei Kameya, Renpei Sengoku, Junko Takahashi-Fujigasaki, Shigeo Murayama, Yasuyuki Iguchi


  • Open Access

    Thrombotic Microangiopathy Presenting with Intestinal Involvement Following Long-term Interferon-β1b Treatment for Multiple Sclerosis

    by Shusaku Omoto, Tomohiro Utsumi, Hiromasa Matsuno, Yuka Terasawa, Yasuyuki Iguchi

    Thrombotic microangiopathies (TMAs) are systemic microvascular occlusive disorders. The present report describes a patient with relapsing-remitting multiple sclerosis who had been treated with interferon (IFN)-β1b therapy for eight years and developed TMA. The patient presented with headache, thrombocytopenia, renal dysfunction, severe hypertension, posterior reversible encephalopathy syndrome, and gastrointestinal involvement. After discontinuation of the medication and initiation of antihypertensive treatment, the patient rapidly improved. This is the first report of TMA with gastrointestinal involvement (intestinal TMA) induced by IFN-β. The new onset of hypertension or headache requires careful attention in cases of long-term administration of IFN-β1b.